Geode Capital Management
ALNY icon

Geode Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Quarter Market Value Status Shares Shares
Change %
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$780M Buy
2,398,770
+75,936
+3% +$24.7M 0.05% 304
2025
Q1
$626M Buy
2,322,834
+116,034
+5% +$31.3M 0.05% 335
2024
Q4
$518M Buy
2,206,800
+59,597
+3% +$14M 0.04% 382
2024
Q3
$589M Buy
2,147,203
+66,928
+3% +$18.4M 0.05% 341
2024
Q2
$505M Buy
2,080,275
+78,557
+4% +$19.1M 0.04% 350
2024
Q1
$299M Buy
2,001,718
+74,982
+4% +$11.2M 0.03% 487
2023
Q4
$368M Buy
1,926,736
+87,231
+5% +$16.7M 0.04% 409
2023
Q3
$325M Buy
1,839,505
+37,483
+2% +$6.63M 0.04% 412
2023
Q2
$342M Buy
1,802,022
+63,907
+4% +$12.1M 0.04% 400
2023
Q1
$348M Buy
1,738,115
+48,186
+3% +$9.64M 0.05% 383
2022
Q4
$401M Buy
1,689,929
+90,455
+6% +$21.5M 0.06% 335
2022
Q3
$320M Buy
1,599,474
+26,771
+2% +$5.35M 0.05% 364
2022
Q2
$229M Buy
1,572,703
+2,420
+0.2% +$353K 0.03% 461
2022
Q1
$256M Buy
1,570,283
+64,992
+4% +$10.6M 0.03% 482
2021
Q4
$255M Buy
1,505,291
+51,272
+4% +$8.68M 0.03% 488
2021
Q3
$274M Buy
1,454,019
+8,001
+0.6% +$1.51M 0.04% 448
2021
Q2
$245M Buy
1,446,018
+59,719
+4% +$10.1M 0.03% 470
2021
Q1
$195M Buy
1,386,299
+77,166
+6% +$10.9M 0.03% 506
2020
Q4
$170M Buy
1,309,133
+49,330
+4% +$6.4M 0.03% 511
2020
Q3
$183M Sell
1,259,803
-24,493
-2% -$3.56M 0.04% 430
2020
Q2
$190M Sell
1,284,296
-69,632
-5% -$10.3M 0.04% 390
2020
Q1
$147M Buy
1,353,928
+114,441
+9% +$12.4M 0.04% 398
2019
Q4
$143M Buy
1,239,487
+50,788
+4% +$5.84M 0.03% 496
2019
Q3
$95.5M Buy
1,188,699
+128,504
+12% +$10.3M 0.02% 587
2019
Q2
$76.9M Buy
1,060,195
+53,973
+5% +$3.91M 0.02% 673
2019
Q1
$94M Buy
1,006,222
+90,689
+10% +$8.47M 0.02% 561
2018
Q4
$66.7M Buy
915,533
+34,770
+4% +$2.53M 0.02% 619
2018
Q3
$77M Buy
880,763
+74,018
+9% +$6.47M 0.02% 602
2018
Q2
$79.4M Buy
806,745
+41,401
+5% +$4.07M 0.02% 576
2018
Q1
$91.1M Buy
765,344
+17,698
+2% +$2.11M 0.03% 523
2017
Q4
$94.9M Buy
747,646
+88,119
+13% +$11.2M 0.03% 503
2017
Q3
$77.5M Sell
659,527
-2,878
-0.4% -$338K 0.03% 533
2017
Q2
$52.8M Buy
662,405
+85,608
+15% +$6.83M 0.02% 632
2017
Q1
$29.6M Buy
576,797
+42,781
+8% +$2.19M 0.01% 896
2016
Q4
$20M Buy
534,016
+14,111
+3% +$528K 0.01% 1081
2016
Q3
$35.2M Buy
519,905
+20,289
+4% +$1.37M 0.02% 699
2016
Q2
$27.7M Buy
499,616
+19,435
+4% +$1.08M 0.02% 761
2016
Q1
$30.1K Buy
480,181
+31,627
+7% +$1.98K 0.02% 711
2015
Q4
$42.2M Buy
448,554
+10,371
+2% +$976K 0.02% 571
2015
Q3
$35.2M Buy
438,183
+3,827
+0.9% +$307K 0.02% 625
2015
Q2
$52M Buy
434,356
+23,380
+6% +$2.8M 0.03% 517
2015
Q1
$42.9M Buy
410,976
+63,014
+18% +$6.58M 0.02% 566
2014
Q4
$33.8M Buy
347,962
+18,137
+5% +$1.76M 0.02% 627
2014
Q3
$25.8M Buy
329,825
+5,617
+2% +$439K 0.02% 709
2014
Q2
$20.5M Buy
324,208
+10,614
+3% +$670K 0.01% 833
2014
Q1
$21.1M Buy
313,594
+28,989
+10% +$1.95M 0.01% 789
2013
Q4
$18.3M Buy
284,605
+32,238
+13% +$2.07M 0.01% 831
2013
Q3
$16.2M Buy
252,367
+32,709
+15% +$2.09M 0.01% 791
2013
Q2
$6.81M Buy
+219,658
New +$6.81M 0.01% 1210